Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

New Strategies to Uncover Genes Involved in the Development of Prostate Cancer in Families with Multiple Cases.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

RNA-Seq and XAI Can be Used as Tools to Aid Pathologists in the Process of Cancer Diagnosis.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Artificial Intelligence for CELLSEARCH Image Analysis.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Automated Analysis of Liquid Biopsy Using Deep Learning: Detecting Circulating Tumor Cells and Cancer-Associated Fibroblasts.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Bioinformatics of Shallow Whole Genome Sequencing Data of Circulating Tumor Cells to Inform Cancer Diagnosis and Treatment.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Culture and Expansion of Circulating Tumor Cells from Breast Malignant Effusions as Organoids.

Methods in molecular biology (Clifton, N.J.)·2026

Search research articles

Related Experiment Video

Updated: Apr 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Planning an Academic Clinical Trial.

Kim M Champion¹, Gemma R Jones

¹Joint Research Office, University College London, Gower Street, London, WC1E 6BT, UK, k.champion@ucl.ac.uk.

Methods in Molecular Biology (Clifton, N.J.)

|June 15, 2015

Summary

This chapter outlines regulatory requirements for clinical trials involving investigational medicinal products (IMPs), with a focus on gene therapies. It provides guidance for academic sponsors in the UK and Europe to ensure compliant and successful trial execution.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Related Experiment Videos

Last Updated: Apr 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Area of Science:

Clinical Pharmacology and Toxicology
Biotechnology and Genetic Engineering

Background:

Clinical trials are essential for evaluating investigational medicinal products (IMPs), including advanced biological therapies like gene therapies.
Gene therapies offer significant therapeutic potential but present unique regulatory and logistical challenges due to their complexity and the need for specialized handling.
Navigating the regulatory landscape is critical for the safe and legal development, manufacturing, and administration of these novel treatments.

Purpose of the Study:

To summarize standard requirements for clinical trials with investigational medicinal products (IMPs).
To detail additional considerations for trials involving gene therapies and genetically modified microorganisms (GMMs).
To provide guidance for UK non-commercial sponsors, referencing UK and European legislation and guidance.

Main Methods:

Review and synthesis of existing regulatory frameworks and guidance documents relevant to clinical trials in the UK and Europe.
Focus on requirements specific to biological medicinal products, gene therapies, and genetically modified microorganisms.
Perspective adopted from a UK academic (non-commercial) sponsor.

Main Results:

Identification of standard requirements applicable to all IMP clinical trials.
Elucidation of specific, heightened requirements for gene therapy and GMM trials.
Emphasis on the importance of understanding and adhering to regulatory guidelines for compliance and success.

Conclusions:

Successful clinical trials with advanced therapies necessitate a thorough understanding of the regulatory environment.
Specific guidance for gene therapies and GMMs is crucial for safe and legal trial conduct.
The principles discussed are broadly applicable across European Member States and beyond for gene therapy trials.